csl

CSL said developing new and better vaccines is a strategic priority for the company going forward.

CSL is setting its sights on the US$21.6 billion (AU$33.54 billion) asthma market with the development of a ...

Commonwealth Serum Laboratories (CSL), an Australian biotechnology company and the world's second-biggest flu vaccine manufacturer, has agreed to ...

The University of Queensland announced its collaboration with Moderna to use mRNA research for vaccine development of diseases ...

The first cell-based Influenza vaccine in Australia has been approved for use in adults and children aged two ...